Agilent Technologies, Inc. (A)

Agilent Technologies' stock has been influenced by several analyst rating adjustments and its quarterly earnings reports. In Q4 2025, Agilent beat revenue estimates and forecast fiscal year 2026 revenue slightly ahead of expectations. Several analysts lowered their price targets for Agilent Technologies between February and April 2026. In Q1 2026, Agilent reported solid financial results, with revenue increasing by 7.0% from the previous year, and raised its fiscal year 2026 revenue outlook. Agilent received FDA approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma on March 26, 2026, and announced the BioTek Cytation 9 Cell Imaging Multimode Reader on April 1, 2026.

Demand for Agilent Technologies' products and services can experience seasonality, influenced by customer capital spending policies, research and development budgets, government funding policies, and seasonal surges in sample workload. The demand for Agilent's offerings is subject to cyclical and seasonal trends within the broader life sciences, diagnostics, and applied chemical markets.

Agilent Technologies, Inc. is a global leader in life sciences, diagnostics, and applied chemical markets, providing a comprehensive range of solutions for laboratories worldwide. The company specializes in the design, manufacturing, and marketing of measurement instruments and is organized into three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. Agilent's offerings enable customers to identify, quantify, and analyze the physical and biological properties of substances and products, supporting cutting-edge research, patient diagnostics, and testing for the safety of water, food, and pharmaceuticals.

Agilent Technologies maintains a significant global presence, serving customers in 110 countries. The company's worldwide capabilities include sales offices, logistics centers, and business facilities in three major geographies, with its headquarters located in Santa Clara, California, U.S. Agilent has facilities in approximately 30 countries, encompassing R&D, manufacturing, sales, and support operations.

Agilent Technologies has maintained a strong brand reputation, marked by recognition for its corporate responsibility and employee satisfaction. Agilent was named one of the Most JUST Companies in America by Just Capital and CNBC for the sixth consecutive year. Agilent is certified as a Great Place to Work® in 27 countries and territories. Agilent was also named to The Sustainability Yearbook 2024 by S&P Global.

Agilent Technologies, Inc. is primarily institutionally owned, with institutional investors holding a significant majority of the company's shares. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and Massachusetts Financial Services Co /ma/. Individual ownership is comparatively small.